4.5 Article

Transglutaminase-catalyzed covalent multimerization of camelidae anti-human TNF single domain antibodies improves neutralizing activity

期刊

JOURNAL OF BIOTECHNOLOGY
卷 142, 期 2, 页码 170-178

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jbiotec.2009.04.002

关键词

hTNF; Single domain antibody; VHH; Transglutaminase; Enbrel; Nanobody

资金

  1. Deutsche Forschungsgemeinschaft [SFB415]

向作者/读者索取更多资源

Tumor necrosis factor (TNF) plays an important role in chronic inflammatory disorders, such as Rheumatoid Arthritis and Crohn's disease. Recently, monoclonal Camelidae variable heavy-chain domain-only antibodies (VHH) were developed to antagonize the action of human TNF (hTNIF). Here. we show that hTNF-VHH does not interfere with hTNF trimerization, but competes with hTNF for hTNF-receptor binding. Moreover, we describe posttranslational dimerization and multimerization of hTNF-VHH molecules in vitro catalyzed by microbial transglutaminases (MTG). The ribonuclease S-tag-peptide was shown to act as a peptidyl substrate in covalent protein cross-linking reactions catalyzed by MTG from Streptomyces mobaraensis. The S-tag sequence was C-terminally fused to the hTNF-VHH and the fusion protein was expressed and purified from Escherichia coli culture supernatants. hTNF-VHH-S-tag fusion proteins were efficiently dimerized and multimerized by MTG whereas hTNF-VHH was not susceptible to protein cross-linking. Cell cytotoxicity assays, using hTNF as apoptosis inducing cytokine, revealed that dimerized and multimerized hTNF-VHH proteins were much more active than the monomeric hTNF-VHH. We hypothesize that improved inhibition by dimeric and multimeric single chain hTNF-VHH proteins is caused by avidity effects. (C) 2009 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据